NEUSTAR
14.8.2019 09:02:04 CEST | Business Wire | Press release
Small-scale Distributed Denial of Service (DDoS) attacks are becoming more frequent and sophisticated, according to new research from Neustar ’s Security Operations Centre (SOC). Released today, the Q2, 2019 Cyber Threats and Trends report reveals that between April and June of this year, over 75 percent of all attacks mitigated by Neustar were 5 Gigabits per second (Gbps) or less, while large attacks – those of 100 Gbps and over – decreased by 64 percent.
At first glance, the evolution of DDoS attacks on enterprises seems to follow a pattern. The overall number of attacks during Q2 2019 compared with the previous year grew by 133 percent, which, though down from last quarter’s 200% growth, is still high. Stepping outside an analysis of the numbers of attacks to their composition, however, shows some interesting changes, according to Neustar.
Small and secretive
DDoS attacks have long been considered overwhelming threats and are traditionally associated with high rates of traffic. Such attacks do continue to take place, but smaller and more carefully targeted incursions are growing in quantity, intensity and duration. Such attacks do not seek to saturate the network link – and draw unwanted attention in the process – but to degrade or disable specific infrastructure within the target. Such lower volume incursions may enable the perpetrator to get in and get out unnoticed, or allow the attack to continue for quite a long time undetected. In fact, the longest duration for a single attack in Q2 was nearly two days.
These small attacks pose a significant threat, as they fall below the typical threshold that enterprises with a “detect and alert” DDoS mitigation strategy might employ. An attacker could therefore affect targets ranging from infrastructure to individual servers with relative impunity.
The situation becomes more alarming when considering an enterprise’s ability to recognise such threats when they were underway. When asked how likely they would be to notice today’s most prevalent smaller attacks, a staggering 72 percent of CTOs, CISOs and Directors of Security from the Neustar International Security Council (NISC) answered very unlikely, somewhat unlikely or somewhat likely. The remaining 28 percent of respondents felt it was very likely that they would notice a small-scale DDoS attack.
“With the rise of smaller DDoS attacks going under the radar, now is the time for organisations to deploy an ‘always on’ DDoS mitigation service that is constantly monitoring traffic to ensure threats of all sizes are detected, managed and diffused,” said Rodney Joffe, Senior Vice President, Senior Technologist and Fellow at Neustar.
“Now, with most of today’s attacks directed at specific services, gateways and applications – therefore requiring less traffic to bring it down – a greater level of understanding from businesses to determine the protection they need is essential. The first stage of this is to determine what is valuable, not what is vulnerable. One of the best ways to separate vulnerability from value is to create a ‘risk register’ that starts from the inside and focuses on your most critical business assets,” Joffe added.
A complimentary copy of The Neustar Q2’19 Cyber Threats and Trends Report is available here .
- ENDS -
About Neustar, Inc.
Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005036/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
